TY - JOUR
T1 - The impact of sars-cov-2 pandemic on time to primary, secondary resection and adjuvant intravesical therapy in patients with high-risk non-muscle invasive bladder cancer: A retrospective multi-institutional cohort analysis
AU - Ferro, Matteo
AU - Del Giudice, Francesco
AU - Carrieri, Giuseppe
AU - Busetto, Gian Maria
AU - Cormio, Luigi
AU - Hurle, Rodolfo
AU - Contieri, Roberto
AU - Arcaniolo, Davide
AU - Sciarra, Alessandro
AU - Maggi, Martina
AU - Porpiglia, Francesco
AU - Manfredi, Matteo
AU - Fiori, Cristian
AU - Antonelli, Alessandro
AU - Tafuri, Alessandro
AU - Bove, Pierluigi
AU - Terrone, Carlo
AU - Borghesi, Marco
AU - Costantini, Elisabetta
AU - Iliano, Ester
AU - Montanari, Emanuele
AU - Boeri, Luca
AU - Russo, Giorgio Ivan
AU - Madonia, Massimo
AU - Tedde, Alessandro
AU - Veccia, Alessandro
AU - Simeone, Claudio
AU - Liguori, Giovanni
AU - Trombetta, Carlo
AU - Brunocilla, Eugenio
AU - Schiavina, Riccardo
AU - Dal Moro, Fabrizio
AU - Racioppi, Marco
AU - Vartolomei, Mihai Dorin
AU - Longo, Nicola
AU - Spirito, Lorenzo
AU - Crocetto, Felice
AU - Cantiello, Francesco
AU - Damiano, Rocco
AU - Di Stasi, Savino M.
AU - Marchioni, Michele
AU - Schips, Luigi
AU - Parma, Paolo
AU - Carmignani, Luca
AU - Conti, Andrea
AU - Soria, Francesco
AU - Gontero, Paolo
AU - Barone, Biagio
AU - Deho, Federico
AU - Zaffuto, Emanuele
AU - Papalia, Rocco
AU - Scarpa, Roberto M.
AU - Pagliarulo, Vincenzo
AU - Lucarelli, Giuseppe
AU - Ditonno, Pasquale
AU - Botticelli, Francesco Maria Gerardo
AU - Musi, Gennaro
AU - Catellani, Michele
AU - de Cobelli, Ottavio
N1 - Funding Information:
The authors would like to express their deepest gratitude to Fondazione Muto Onlus in Naples for the support of the publication of this manuscript.
Publisher Copyright:
© 2021 by the authors. Licensee MDPI, Basel, Switzerland.
PY - 2021/11/1
Y1 - 2021/11/1
N2 - Background: To investigate the impact of COVID-19 outbreak on the diagnosis and treatment of non-muscle invasive bladder cancer (NMIBC). Methods: A retrospective analysis was per-formed using an Italian multi-institutional database of TURBT patients with high-risk urothelial NMIBC between January 2019 and February 2021, followed by Re-TURBT and/or adjuvant intravesical BCG. Results: A total of 2591 patients from 27 institutions with primary TURBT were included. Of these, 1534 (59.2%) and 1056 (40.8%) underwent TURBT before and during the COVID-19 out-break, respectively. Time between diagnosis and TURBT was significantly longer during the COVID-19 period (65 vs. 52 days, p = 0.002). One thousand and sixty-six patients (41.1%) received Re-TURBT, 604 (56.7%) during the pre-COVID-19. The median time to secondary resection was significantly longer during the COVID-19 period (55 vs. 48 days, p < 0.0001). A total of 977 patients underwent adjuvant intravesical therapy after primary or secondary resection, with a similar distribution across the two groups (n = 453, 86% vs. n = 388, 86.2%). However, the proportion of the patients who underwent maintenance significantly differed (79.5% vs. 60.4%, p < 0.0001). Conclusions: The COVID-19 pandemic represented an unprecedented challenge to our health system. Our study did not show significant differences in TURBT quality. However, a delay in treatment schedule and disease management was observed. Investigation of the oncological impacts of those differences should be advocated.
AB - Background: To investigate the impact of COVID-19 outbreak on the diagnosis and treatment of non-muscle invasive bladder cancer (NMIBC). Methods: A retrospective analysis was per-formed using an Italian multi-institutional database of TURBT patients with high-risk urothelial NMIBC between January 2019 and February 2021, followed by Re-TURBT and/or adjuvant intravesical BCG. Results: A total of 2591 patients from 27 institutions with primary TURBT were included. Of these, 1534 (59.2%) and 1056 (40.8%) underwent TURBT before and during the COVID-19 out-break, respectively. Time between diagnosis and TURBT was significantly longer during the COVID-19 period (65 vs. 52 days, p = 0.002). One thousand and sixty-six patients (41.1%) received Re-TURBT, 604 (56.7%) during the pre-COVID-19. The median time to secondary resection was significantly longer during the COVID-19 period (55 vs. 48 days, p < 0.0001). A total of 977 patients underwent adjuvant intravesical therapy after primary or secondary resection, with a similar distribution across the two groups (n = 453, 86% vs. n = 388, 86.2%). However, the proportion of the patients who underwent maintenance significantly differed (79.5% vs. 60.4%, p < 0.0001). Conclusions: The COVID-19 pandemic represented an unprecedented challenge to our health system. Our study did not show significant differences in TURBT quality. However, a delay in treatment schedule and disease management was observed. Investigation of the oncological impacts of those differences should be advocated.
KW - Bladder cancer
KW - Intravesical BCG
KW - Re-TURBT
KW - SARS-CoV-2
KW - Trans-urethral resection of bladder tumor
UR - http://www.scopus.com/inward/record.url?scp=85117278545&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85117278545&partnerID=8YFLogxK
U2 - 10.3390/cancers13215276
DO - 10.3390/cancers13215276
M3 - Article
AN - SCOPUS:85117278545
VL - 13
SP - 5276
JO - Cancers
JF - Cancers
SN - 2072-6694
IS - 21
ER -